Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCD19 CAR T Cells in R/R B-NHL
NCT04240808Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Jul 2020
- Primary completion
- Mar 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cd19car-cd3zeta-4-1bb autologous t-lymphocyte cells in B-cell non-Hodgkin lymphoma, sponsored by University of Colorado Denver. Primary endpoints: Successful manufacture of UCD19 CAR T Cells at Day 0, Percent of Participants successfully infused with UCD19 CAR T Cells at Day 0 and 1 more. Started Jul 2020; status: completed.
02
Drugs
cd19car-cd3zeta-4-1bb autologous t-lymphocyte cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04240808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240808.